Monitoring imatinib plasma concentrations in chronic myeloid leukemia by Darlize Hübner Martins, Sandrine Comparsi Wagner, Tamyris Vianna dos Santos, Lilian de Lima Feltraco Lizot, Marina Venzon Antunes, Marcelo Capra, Rafael Linden

Get full text

UPDATED PROGRESSION-FREE SURVIVAL (PFS) AND DEPTH OF RESPONSE IN IKEMA, A RANDOMIZED PHASE 3 TRIAL OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE (ISA-KD) VS KD IN RELAPSED MULTIPLE... by Ozgur PEKTAS, Philippe MOREAU, Meletios-Athanasios DIMOPOULOS, Joseph MIKHAEL, Kwee YONG, Marcelo CAPRA, Thierry FACON, Roman HAJEK, Ivan ŠPIČKA, France CASCA, Sandrine MACÉ, Marie-Laure RISSE, Thomas MARTIN

Get full text

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA (IKEMA): FINAL OVERALL SURVIVAL ANALYSIS by Ecenur Guder Arslan, Kwee Yong, Thomas Martın, Meletios Dımopoulos, Joseph Mıkhael, Marcelo Capra, Thierry Facon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martınez, Chang-Ki Mın, Philippe Moreau

Get full text

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study by Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim, Gracia Martinez, Chang-Ki Min, Ludek Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, France Casca, Sandrine Macé, Marie-Laure Risse, Philippe Moreau

Get full text

Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study by Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim, Gracia Martinez, Chang-Ki Min, Ludek Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, France Casca, Sandrine Macé, Marie-Laure Risse, Philippe Moreau

Get full text

Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study by Alexander Lesokhin, Richard LeBlanc, Meletios A. Dimopoulos, Marcelo Capra, Carmelo Carlo‐Stella, Lionel Karlin, Jean‐Francois Castilloux, Peter Forsberg, Gurdeep Parmar, Axel Tosikyan, Ludek Pour, Vincent Ribrag, Rossella Ribolla, Al‐Ola Abdallah, Nadia Le Roux, Liyan Dong, Helgi van deVelde, Laurent Mayrargue, Lucie Lépine, Sandrine Macé, Philippe Moreau

Get full text

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk by Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay Nooka, Hang Quach, Markus Munder, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Pieter Sonneveld, Tineke Casneuf, Nikki DeAngelis, Himal Amin, Jon Ukropec, Rachel Kobos, Maria-Victoria Mateos

Get full text